CGTX Soars 11.11% on Clinical Trial Progress, Analyst Optimism

Cognition Therapeutics, Inc. Common Stock (CGTX) surged 11.11% in pre-market trading on July 7, 2025, driven by significant developments in its clinical trials and analyst ratings.

Cognition Therapeutics has reported over 50% enrollment in its Phase 2 START study for Alzheimer's treatment, marking a substantial milestone in its clinical development. This progress has bolstered investor confidence in the company's potential to bring innovative treatments to market.

Analysts have also shown optimism towards Cognition Therapeutics. Wainwright reiterated its Buy rating and set a price target of $3.00, reflecting positive sentiment towards the company's prospects. Additionally, three analysts from TipRanks have weighed in on the stock, further contributing to the bullish outlook.

With these developments, Cognition Therapeutics is poised to continue its upward trajectory, as investors anticipate the company's upcoming earnings report on August 14, 2025. The combination of clinical progress and analyst support has created a favorable environment for the stock, driving its recent pre-market surge.